Clinical Trial: Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With ADHD and Cannabis Use Disorder

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838311) titled 'Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With ADHD and Cannabis Use Disorder' on Sept. 17.

Brief Summary: The goal of this clinical trial is to look at how delayed-release, extended-release methylphenidate (Jornay PM), an FDA-approved medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), works to treat ADHD symptoms in adolescents and young adults (ages 16-26) with ADHD and Cannabis Use Disorder. Researchers will compare delayed-release, extended-release methylphenidate to a placebo (a look-alike substance that contains no drug).

Participants will be ...